Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment

Kavitha Gopal, Timothy C. Johnson, Saraswathi Gopal, Aaron Walfish, Christine T. Bang, Pauline Suwandhi, Helene N. Pena-Sahdala, David J. Clain, Henry C. Bodenheimer, Albert D. Min

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

The low-density lipoprotein receptor (LDLR) has been proposed as a candidate receptor for the hepatitis C virus (HCV). Competitive inhibition of HCV binding to the LDLR by low-density lipoprotein (LDL) has been shown in vitro. If similar inhibition occurs in vivo, an elevated serum concentration of beta-lipoproteins may reduce the efficiency of infecting hepatocytes with HCV by competitively inhibiting HCV viral receptor binding. We investigated the role of baseline lipid values in influencing the outcome of HCV treatment. We conducted a retrospective chart review of patients treated with an interferon-based regimen at our liver and gastroenterology clinics between 1998 and 2004. Of 99 patients enrolled in the study, 49 (49.5%) had HCV genotype 1 (LDL 100.2 ± 30.2 mg/dL [mean ± SD]), and 50 patients (50.5%) had genotype 2 or 3 (LDL 110.1 ± 40 mg/dL) infection. Early viral response (EVR), end-of-treatment response (ETR), and sustained viral response (SVR) were documented in 99, 88, and 77 patients, respectively. LDL and cholesterol levels prior to treatment were found to be higher in patients with positive EVR, ETR, and SVR. This difference remained significant independent of age. Multivariate analysis controlling for genotype and age showed that the higher the cholesterol and LDL levels prior to treatment, the greater the odds of responding to treatment. In conclusion, having higher serum LDL and cholesterol levels before treatment may be significant prognostic indicators for treatment outcome of those with chronic hepatitis C infection, particularly in genotypes 1 and 2.

Original languageEnglish (US)
Pages (from-to)335-340
Number of pages6
JournalHepatology
Volume44
Issue number2
DOIs
StatePublished - Aug 2006

Fingerprint

Hepatitis C
LDL Lipoproteins
Hepacivirus
Genotype
LDL Receptors
LDL Cholesterol
Therapeutics
Virus Receptors
Virus Attachment
Chronic Hepatitis C
Gastroenterology
Infection
Serum
Interferons
HDL Cholesterol
Hepatocytes
Multivariate Analysis
Lipids
Liver

ASJC Scopus subject areas

  • Hepatology

Cite this

Gopal, K., Johnson, T. C., Gopal, S., Walfish, A., Bang, C. T., Suwandhi, P., ... Min, A. D. (2006). Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology, 44(2), 335-340. https://doi.org/10.1002/hep.21261

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. / Gopal, Kavitha; Johnson, Timothy C.; Gopal, Saraswathi; Walfish, Aaron; Bang, Christine T.; Suwandhi, Pauline; Pena-Sahdala, Helene N.; Clain, David J.; Bodenheimer, Henry C.; Min, Albert D.

In: Hepatology, Vol. 44, No. 2, 08.2006, p. 335-340.

Research output: Contribution to journalArticle

Gopal, K, Johnson, TC, Gopal, S, Walfish, A, Bang, CT, Suwandhi, P, Pena-Sahdala, HN, Clain, DJ, Bodenheimer, HC & Min, AD 2006, 'Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment', Hepatology, vol. 44, no. 2, pp. 335-340. https://doi.org/10.1002/hep.21261
Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology. 2006 Aug;44(2):335-340. https://doi.org/10.1002/hep.21261
Gopal, Kavitha ; Johnson, Timothy C. ; Gopal, Saraswathi ; Walfish, Aaron ; Bang, Christine T. ; Suwandhi, Pauline ; Pena-Sahdala, Helene N. ; Clain, David J. ; Bodenheimer, Henry C. ; Min, Albert D. / Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. In: Hepatology. 2006 ; Vol. 44, No. 2. pp. 335-340.
@article{7852bfc3658745d4aa129e2a5dd0ce64,
title = "Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment",
abstract = "The low-density lipoprotein receptor (LDLR) has been proposed as a candidate receptor for the hepatitis C virus (HCV). Competitive inhibition of HCV binding to the LDLR by low-density lipoprotein (LDL) has been shown in vitro. If similar inhibition occurs in vivo, an elevated serum concentration of beta-lipoproteins may reduce the efficiency of infecting hepatocytes with HCV by competitively inhibiting HCV viral receptor binding. We investigated the role of baseline lipid values in influencing the outcome of HCV treatment. We conducted a retrospective chart review of patients treated with an interferon-based regimen at our liver and gastroenterology clinics between 1998 and 2004. Of 99 patients enrolled in the study, 49 (49.5{\%}) had HCV genotype 1 (LDL 100.2 ± 30.2 mg/dL [mean ± SD]), and 50 patients (50.5{\%}) had genotype 2 or 3 (LDL 110.1 ± 40 mg/dL) infection. Early viral response (EVR), end-of-treatment response (ETR), and sustained viral response (SVR) were documented in 99, 88, and 77 patients, respectively. LDL and cholesterol levels prior to treatment were found to be higher in patients with positive EVR, ETR, and SVR. This difference remained significant independent of age. Multivariate analysis controlling for genotype and age showed that the higher the cholesterol and LDL levels prior to treatment, the greater the odds of responding to treatment. In conclusion, having higher serum LDL and cholesterol levels before treatment may be significant prognostic indicators for treatment outcome of those with chronic hepatitis C infection, particularly in genotypes 1 and 2.",
author = "Kavitha Gopal and Johnson, {Timothy C.} and Saraswathi Gopal and Aaron Walfish and Bang, {Christine T.} and Pauline Suwandhi and Pena-Sahdala, {Helene N.} and Clain, {David J.} and Bodenheimer, {Henry C.} and Min, {Albert D.}",
year = "2006",
month = "8",
doi = "10.1002/hep.21261",
language = "English (US)",
volume = "44",
pages = "335--340",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment

AU - Gopal, Kavitha

AU - Johnson, Timothy C.

AU - Gopal, Saraswathi

AU - Walfish, Aaron

AU - Bang, Christine T.

AU - Suwandhi, Pauline

AU - Pena-Sahdala, Helene N.

AU - Clain, David J.

AU - Bodenheimer, Henry C.

AU - Min, Albert D.

PY - 2006/8

Y1 - 2006/8

N2 - The low-density lipoprotein receptor (LDLR) has been proposed as a candidate receptor for the hepatitis C virus (HCV). Competitive inhibition of HCV binding to the LDLR by low-density lipoprotein (LDL) has been shown in vitro. If similar inhibition occurs in vivo, an elevated serum concentration of beta-lipoproteins may reduce the efficiency of infecting hepatocytes with HCV by competitively inhibiting HCV viral receptor binding. We investigated the role of baseline lipid values in influencing the outcome of HCV treatment. We conducted a retrospective chart review of patients treated with an interferon-based regimen at our liver and gastroenterology clinics between 1998 and 2004. Of 99 patients enrolled in the study, 49 (49.5%) had HCV genotype 1 (LDL 100.2 ± 30.2 mg/dL [mean ± SD]), and 50 patients (50.5%) had genotype 2 or 3 (LDL 110.1 ± 40 mg/dL) infection. Early viral response (EVR), end-of-treatment response (ETR), and sustained viral response (SVR) were documented in 99, 88, and 77 patients, respectively. LDL and cholesterol levels prior to treatment were found to be higher in patients with positive EVR, ETR, and SVR. This difference remained significant independent of age. Multivariate analysis controlling for genotype and age showed that the higher the cholesterol and LDL levels prior to treatment, the greater the odds of responding to treatment. In conclusion, having higher serum LDL and cholesterol levels before treatment may be significant prognostic indicators for treatment outcome of those with chronic hepatitis C infection, particularly in genotypes 1 and 2.

AB - The low-density lipoprotein receptor (LDLR) has been proposed as a candidate receptor for the hepatitis C virus (HCV). Competitive inhibition of HCV binding to the LDLR by low-density lipoprotein (LDL) has been shown in vitro. If similar inhibition occurs in vivo, an elevated serum concentration of beta-lipoproteins may reduce the efficiency of infecting hepatocytes with HCV by competitively inhibiting HCV viral receptor binding. We investigated the role of baseline lipid values in influencing the outcome of HCV treatment. We conducted a retrospective chart review of patients treated with an interferon-based regimen at our liver and gastroenterology clinics between 1998 and 2004. Of 99 patients enrolled in the study, 49 (49.5%) had HCV genotype 1 (LDL 100.2 ± 30.2 mg/dL [mean ± SD]), and 50 patients (50.5%) had genotype 2 or 3 (LDL 110.1 ± 40 mg/dL) infection. Early viral response (EVR), end-of-treatment response (ETR), and sustained viral response (SVR) were documented in 99, 88, and 77 patients, respectively. LDL and cholesterol levels prior to treatment were found to be higher in patients with positive EVR, ETR, and SVR. This difference remained significant independent of age. Multivariate analysis controlling for genotype and age showed that the higher the cholesterol and LDL levels prior to treatment, the greater the odds of responding to treatment. In conclusion, having higher serum LDL and cholesterol levels before treatment may be significant prognostic indicators for treatment outcome of those with chronic hepatitis C infection, particularly in genotypes 1 and 2.

UR - http://www.scopus.com/inward/record.url?scp=33747050665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747050665&partnerID=8YFLogxK

U2 - 10.1002/hep.21261

DO - 10.1002/hep.21261

M3 - Article

C2 - 16871569

AN - SCOPUS:33747050665

VL - 44

SP - 335

EP - 340

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -